NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

A cost effectiveness analysis of finasteride and TURP in the treatment of benign prostatic hyperplasia.

Baladi JF, Menon D, Jacobs P; International Society of Technology Assessment in Health Care. Meeting.

Annu Meet Int Soc Technol Assess Health Care Int Soc Technol Assess Health Care Meet. 1995; 11: Abstract No. 21.

CCOHTA, Ottawa, Canada.

OBJECTIVE. To assess the cost effectiveness of Finasteride and TURP in treatment of benign prostatic hyperplasia (BPH) from the perspective of the Canadian provincial health care system. METHODS. A decision analysis is built based upon the information provided about the different treatment paths and the effectiveness of the therapies under consideration in the Clinical Practice Guidelines published by the US Agency for Health Care Policy and Research. A cost effectiveness analysis is then conducted using cost figures collected from the various Canadian federal and provincial agencies. Only direct costs relevant to the health care system are considered. In addition, the symptom severity scale as well as the degree of "bothersomeness" are reprocessed into a Rosser quality of life index. QALYs are consequently derived for each treatment option. RESULTS. The life expectancy is a crucial determinant of the cost-effectiveness of Finasteride and TURP. The cost-utility analysis reveals that for mild symptoms, TURP could actually lead to a decrease in QALYs. Also, Finasteride therapy appears to be more cost effective for persons over a certain age wheras TURP appears to be more cost effective for persons under this age. CONCLUSIONS. In instances where the treatment option is elective, and if cost-effectiveness is a determining factor, age will determine the first line treatment of choice for patients suffering from moderate to severe BPH related symptoms.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Canada
  • Cost-Benefit Analysis
  • Decision Support Techniques
  • Finasteride
  • Humans
  • Hyperthermia, Induced
  • Male
  • Prostatectomy
  • Prostatic Hyperplasia
  • Quality-Adjusted Life Years
  • Transurethral Resection of Prostate
  • economics
  • surgery
  • therapy
  • hsrmtgs
Other ID:
  • HTX/96648757
UI: 102215775

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov